Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking

Regulations by 2FIRSTS.ai
May.17.2024
Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking
Study at GRELL 2024 reveals 80% of Brazil lung cancer deaths linked to smoking, causing concerns for public health.

According to a report from Brazilian media SBTNEWS on May 16th, a study presented at the Latin American Cancer Epidemiology and Registration Organization annual meeting (GRELL 2024) held by the Cancer Foundation in Switzerland revealed that 80% of male and female lung cancer deaths in Brazil are related to smoking (nicotine dependence). Alfredo Scaff, medical advisor at the Cancer Foundation, stated that the purpose of this study is to present data that can help prevent the disease to society.

 

A standard journalistic translation is: Skaf believes that there is a direct relationship between lung cancer and smoking habits, stating that "strictly speaking, smoking is currently the main cause of cancer worldwide, especially in Brazil.

 

There is controversy surrounding the use of e-cigarettes as a method to quit smoking, according to Scarf. In most cases, he believes it only leads to a habit of addiction to smoking. Scarf has warned that e-cigarettes may further increase the death rate from lung cancer caused by smoking. He also reminds people to be aware that nicotine is the most addictive substance in legal drugs.

 

A study has shown that the annual cost of lung cancer in Brazil reaches up to 9 billion Reais, including direct medical expenses, loss of productivity, and care for patients. However, the tobacco industry only covers 10% of the total expenses related to lung cancer in Brazil, amounting to 125 billion Reais.

 

Skaf pointed out that smoking not only leads to lung cancer but also to tooth decay, damage to the mouth and throat, chronic obstructive pulmonary disease, hypertension, acute myocardial infarction, and stroke. All of these contribute to increased direct costs in the public domain, such as treatment expenses, as well as indirect costs like productivity losses, budget expenditures, and so on.

 

The National Cancer Institute of Brazil predicts that this year there will be 14,000 new cases of lung cancer in women and 18,000 new cases in men. Additionally, the research found that the majority of patients, whether male (63.1%) or female (63.9%), seek medical attention when the disease has already reached an advanced stage. This is a widespread phenomenon across all regions of Brazil.

 

Researchers from the Cancer Foundation analyzed global data from the International Agency for Research on Cancer (IARC) and found that if current smoking patterns continue, the incidence and mortality rates of lung cancer are projected to increase by over 65% and 74% respectively by the year 2040 compared to 2022.

 

In the southern region, smoking is very common. The incidence of lung cancer in the southern region is higher, with 24.14 cases per 100,000 for men and 15.54 cases per 100,000 for women, exceeding the national average of 12.73 cases for men and 9.26 cases for women.

 

The incidence rates of lung cancer in men are lower than the national average in the southern and northeastern regions, while the incidence rates in women in the southern, northeastern, and southeastern regions are 8.27 cases, 8.46 cases, and 8.92 cases per 100,000 people, respectively, also lower than the national average. In all age groups, the male lung cancer mortality rate in the southern region is the highest in the country. According to research, the lung cancer mortality rate in men aged 40-59 in the southern region is 16.03 cases per 100,000 people, while for those aged 60 and above, it is 132.26 cases per 100,000 people.

 

According to information from the Brazilian news agency, Brazil is facing an even more serious issue as many patients are already in the late stages of their illness when seeking treatment. This is not only the case for male patients (63.1%), but also for female patients (63.9%). This is a trend seen across all regions of Brazil.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland has increased tobacco excise under Budget 2027 and announced a further rise in its E-liquid Products Tax. From Oct. 7, the tax burden on a pack of 20 cigarettes in the most popular price category increased by €1, with pro-rata increases on other tobacco products. The government plans to raise EPT from €0.50 to €0.70 per millilitre from Jan. 1, 2027, a 40% increase applying to both nicotine-containing and nicotine-free e-liquids. The tobacco duty increase is expected to raise about €63.1 million in a full year.
Regulations
Oct.09
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30